PDS Biotechnology announces preclinical publication on CD4 T cell research

PDS Biotechnology announced that new research performed in the laboratory of preeminent CD4 T cell researcher, Andrea Sant, PhD at the University of Rochester Center for Vaccine Biology and Immunology, was published in the peer-reviewed journal, Viruses. The preclinical research studied Infectimune, PDS Biotech’s novel investigational infectious disease immune activating platform, and demonstrated the technology’s potency in eliciting CD4 T cells. The studies focused on comparing Infectimune induced immune responses following primary vaccination against influenza with immune responses induced by leading vaccine adjuvants. The paper, titled, "R-DOTAP cationic lipid nanoparticles outperform squalene-based adjuvant systems in elicitation of CD4 T cells after recombinant influenza hemagglutinin vaccination," reported findings from a preclinical study investigating the ability of Infectimune to promote CD4 T cell responses to vaccination with recombinant influenza protein. Infectimune was compared to AddaVax, which is analogous to commercial adjuvant MF59, and AddaVax combined with CpG, a commercial adjuvant, using HA-B as the influenza vaccine antigen. Results from the study concluded that Infectimune dramatically enhanced CD4 T cell responses to recombinant HA-B proteins relative to AddaVax and AddaVax plus CpG. Further, the Infectimune elicited CD4 T cells displayed abundant Interferon (IFN)-gamma and Interleukin (IL)-2 production that are critical for protective immunity.